FGFR4 and hepatocellular carcinoma: Blueprint Medicines Corp reported the remarkable drug BLU9931, a small irreversible inhibitor of FGFR4. It is currently in the pre-clinical stage of development for HCC and has not been approved by the U.S. FDA.